BioPharmSignal logoBioPharmSignal

Biotech News

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Sarepta Therapeutics (SRPT)Sarepta TherapeuticsFDA / regulatory

– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to traditional approval CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 19, 2026-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic

Related news

SRPTSarepta Therapeutics2026-06-30 12:30 EST

Sarepta Announces FDA Acceptance of sNDAs for AMONDYS 45® and VYONDYS 53®

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

MGTXMeiraGTx2026-07-07 11:30 EST

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

NTLAIntellia2026-04-27 11:00 EST

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

MGTXMeiraGTx2026-04-16 11:10 EST

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

GSKGSK plc2026-03-19 12:00 EST

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

RCKTRocket Pharmaceuticals2026-03-27 11:00 EST

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

GSKGSK plc2026-04-28 12:00 EST

Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA

KRYSKrystal Biotech2026-05-18 12:00 EST

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

VYGRVoyager Therapeutics2026-06-01 12:00 EST

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

View all latest news

Sarepta Therapeutics

Precision Genetic Medicine Sarepta Therapeutics develops and commercializes genetic medicines for rare neuromuscular diseases, with a major focus on Duchenne muscular dystrophy. ELEVIDYS ELEVIDYS is an AAV-based gene-transfer therapy that delivers a micro-dystrophin transgene to skeletal muscle. It is indicated for ambulatory patients...

Recent company news

SRPTSarepta Therapeutics2026-08-05 20:05 EST

Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments

SRPTSarepta Therapeutics2026-07-29 21:00 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SRPTSarepta Therapeutics2026-07-27 12:30 EST

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer

SRPTSarepta Therapeutics2026-07-22 12:30 EST

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

SRPTSarepta Therapeutics2026-06-30 20:25 EST

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
16.78 USD
Market cap
1.72B USD
Exchange
NASDAQ
Sector
Gene Therapy
Location
United States